by qfrsolutions | Nov 3, 2017 | News
Source: FierceBiotech AbbVie has posted positive phase 3 psoriasis data on potential blockbuster risankizumab. The IL-23 antibody easily outperformed Johnson & Johnson’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year. Risankizumab...
by qfrsolutions | Oct 1, 2017 | News
Source: PR Newswire Dermavant Sciences, a biopharmaceutical company focused on developing innovative therapies for dermatologic conditions, today announced the appointment of Vince Ippolito as President and Chief Operating Officer. “I am extremely pleased to...
by qfrsolutions | Aug 22, 2017 | News
Source: FierceBiotech Encore Dermatology, formed two years ago as a vehicle for three ex-Valeant products, has picked up a late-stage pipeline drug via a deal with India’s Dr. Reddy’s Laboratories. The Malvern, Pennsylvania, company says it has licensed a...
by qfrsolutions | Aug 17, 2017 | News
Source: PR Newswire Prollenium Medical Technologies Inc., a leading medical device manufacturer, announced today its United States (U.S.) Food and Drug Administration (FDA) approval for its cross-linked hyaluronic acid dermal filler. Ario Khoshbin, Founder and CEO,...
by qfrsolutions | Aug 14, 2017 | News
Source: Nearly one year ago, as the pharma industry was beset by pricing scrutiny, Allergan CEO Brent Saunders pledged to keep his company’s hikes under 10%. Since then, that pricing rule has spread—even among companies that haven’t publicly promised...
